Disc Medicine to present first DISC-3405 clinical data at SOHO 2026
Disc Medicine (NASDAQ: IRON) will present clinical data across two programmes at the Society of Hematologic Oncology Annual Meeting in Houston, Texas, running 9 to 12 September 2026. The centrepiece is an oral presentation of initial Phase 2 data from the RESTORE-PV trial of DISC-3405 in polycythemia vera, marking the first public clinical readout for that candidate.
The RESTORE-PV oral session, scheduled for 9:55 am CT on 10 September, will be delivered by Naseema Gangat of what the company described as an academic medical centre. The data set covers baseline characteristics and safety information for 40 patients enrolled across Cohorts A and B, plus pharmacokinetic, pharmacodynamic, and early efficacy endpoints for the 20 patients in Cohort A. DISC-3405 is described by the company as an anti-TMPRSS6 monoclonal antibody. TMPRSS6 regulates hepcidin expression and, through it, systemic iron availability; suppressing TMPRSS6 raises hepcidin and reduces iron supply to abnormally proliferating red cell progenitors, the mechanism the company is targeting in PV.
Myelofibrosis posters round out the portfolio
DISC-0974, an anti-hemojuvelin antibody directed at anaemia in myelofibrosis, will also receive an oral slot at 9:45 am CT on 10 September. The RALLY-MF dataset presented will carry an April 2026 data cutoff. A third abstract from the company, poster MPN-809, addresses the humanistic burden of anaemia associated with myelofibrosis through a systematic literature review of patient-reported outcomes.
John Quisel, President and Chief Executive Officer of Disc Medicine, said the SOHO presentations "highlight the continued progress of our clinical-stage portfolio of therapies targeting myeloproliferative neoplasms and our commitment to addressing significant unmet needs for patients with these diseases." Neither DISC-3405 nor DISC-0974 is approved in any jurisdiction.
Competitive and regulatory context
Myeloproliferative neoplasms represent a crowded and competitive development landscape. Polycythemia vera, a JAK2-driven clonal disorder, is already addressed by approved agents including ruxolitinib and ropeginterferon alfa-2b, with several newer candidates in late-stage evaluation. Targeting TMPRSS6 is a relatively novel approach in PV; the scientific rationale draws on work originally advanced in beta-thalassaemia and myelodysplastic syndromes, where hepcidin modulation has attracted growing interest from multiple development groups.
In myelofibrosis, anaemia remains a central and poorly managed clinical problem, particularly in patients receiving JAK inhibitors such as ruxolitinib and fedratinib, which can themselves worsen anaemia. Luspatercept has regulatory approval for anaemia in myelofibrosis in both the US and Europe, creating a reference standard against which DISC-0974's RALLY-MF results will be measured by haematologists and investors alike.
For Disc Medicine, the dual readout at SOHO is an important credibility moment. The company's NASDAQ ticker, IRON, reflects its scientific focus on iron biology and haem biosynthesis, an area where it has positioned itself as a specialist. Investors will scrutinise the Cohort A efficacy data for DISC-3405, particularly any signal on haematocrit control or phlebotomy reduction, which are the standard measures of disease management in PV. The RALLY-MF oral will be watched for durability of anaemia response and safety relative to luspatercept. Full data from both programmes are expected to be published in peer-reviewed form in the months following the conference.